The Effect of Levodopa on Pulmonary Function in Parkinson's Disease: A Systematic Review and Meta-Analysis

Clinical Therapeutics

Volumn 34, Issue 5, 2012, Pages 1049-1055

  Monteiro, Larissa ^a   Souza Machado, Adelmir ^a   Valderramas, Silvia ^a   Melo, Ailton ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Levodopa; Parkinson's disease; Pulmonary dysfunction; Respiratory function; Therapeutics

Indexed keywords

LEVODOPA;

CLINICAL TRIAL (TOPIC); DISEASE DURATION; DRUG EFFECT; DRUG EFFICACY; EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION; META ANALYSIS; OUTCOME ASSESSMENT; PARKINSON DISEASE; REVIEW; SYSTEMATIC REVIEW;

ANTIPARKINSON AGENTS; FORCED EXPIRATORY VOLUME; HUMANS; LEVODOPA; LUNG DISEASES; MODELS, STATISTICAL; PARKINSON DISEASE; PEAK EXPIRATORY FLOW RATE; VITAL CAPACITY;

EID: 84860704122     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.03.001     Document Type: Review

References (27)

1. Cotzias G.C. L-Dopa for Parkinsonism. N Engl J Med 1968, 278:630.
2. Cotzias G.C., Papavasiliou P.S., Gellene R. Experimental treatment of parkinsonism with L-Dopa. Neurology 1968, 18:276-277.
3. Truong D.D., Bhidayasiri R., Wolters E. Management of non-motor symptoms in advanced Parkinson disease. J Neurol Sci 2008, 266:216-228.
4. Polatli M., Akyol A., Cildag O., et al. Pulmonary function tests in Parkinson's disease. Eur J Neurol 2001, 8:341-345.
5. Sabate M., Gonzalez I., Ruperez F., et al. Obstructive and restrictive pulmonary dysfunctions in Parkinson's disease. J Neurol Sci 1996, 138:114-119.
6. De Pandis M.F., Starace A., Stefanelli F., et al. Modification of respiratory function parameters in patients with severe Parkinson's disease. Neurol Sci 2002, 23(Suppl 2):S69-S70.
7. Pal P.K., Sathyaprabha T.N., Tuhina P., et al. Pattern of subclinical pulmonary dysfunctions in Parkinson's disease and the effect of levodopa. Mov Disord 2007, 22:420-424.
8. Shill H., Stacy M. Respiratory function in Parkinson's disease. Clin Neurosci 1998, 5:131-135.
9. Gardner W.N., Langdon N., Parkes J.D. Breathing in Parkinson's disease. Adv Neurol 1987, 45:271-274.
10. Vincken W.G., Gauthier S.G., Dollfuss R.E., et al. Involvement of upper-airway muscles in extrapyramidal disorders. A cause of airflow limitation. N Engl J Med 1984, 311:438-442.
11. Estenne M., Hubert M., De Troyer A. Respiratory-muscle involvement in Parkinson's disease. N Engl J Med 1984, 311:1516-1517.
12. Tzelepis G.E., McCool F.D., Friedman J.H., et al. Respiratory muscle dysfunction in Parkinson's disease. Am Rev Respir Dis 1988, 138:266-271.
13. Hovestadt A., Bogaard J.M., Meerwaldt J.D., et al. Pulmonary function in Parkinson's disease. J Neurol Neurosurg Psychiatry 1989, 52:329-333.
14. de Bruin P.F., de Bruin V.M., Lees A.J., et al. Effects of treatment on airway dynamics and respiratory muscle strength in Parkinson's disease. Am Rev Respir Dis 1993, 148:1576-1580.
15. Herer B., Arnulf I., Housset B. Effects of levodopa on pulmonary function in Parkinson's disease. Chest 2001, 119:387-393.
16. Sathyaprabha T.N., Kapavarapu P.K., Pall P.K., et al. Pulmonary functions in Parkinson's disease. Indian J Chest Dis Allied Sci 2005, 47:251-257.
17. Lim A., Leow L., Huckabee M.L., et al. A pilot study of respiration and swallowing integration in Parkinson's disease: "on" and "off" levodopa. Dysphagia 2008, 23:76-81.
18. Zupnick H.M., Brown L.K., Miller A., et al. Respiratory dysfunction due to L-dopa therapy for parkinsonism: diagnosis using serial pulmonary function tests and respiratory inductive plethysmography. Am J Med 1990, 89:109-114.
19. Vercueil L., Linard J.P., Wuyam B., et al. Breathing pattern in patients with Parkinson's disease. Respir Physiol 1999, 118:163-172.
20. Brescia M., Polverino M., De Luca G., et al. Upper airway muscles dysfunction and levodopa responsiveness in Parkinson's disease. Acta Neurol (Napoli) 1992, 14:512-518. V.
21. De Letter M., Santens P., De Bodt M., et al. The effect of levodopa on respiration and word intelligibility in people with advanced Parkinson's disease. Clin Neurol Neurosurg 2007, 109:495-500.
22. Vincken W.G., Darauay C.M., Cosio M.G. Reversibility of upper airway obstruction after levodopa therapy in Parkinson's disease. Chest 1989, 96:210-212.
23. Obenour W.H., Stevens P.M., Cohen A.A., et al. The causes of abnormal pulmonary function in Parkinson's disease. Am Rev Respir Dis 1972, 105:382-387.
24. Jadad A.R., Moore R.A., Carroll D., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 1996, 17:1-12.
25. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum, Hillsdale, New Jersey. 2nd ed.
26. Sabate M., Rodriguez M., Mendez E., et al. Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson disease. Arch Phys Med Rehabil 1996, 77:29-34.
27. Hoehn M.M., Yahr M.D. Parkinsonism: onset, progression, and mortality. Neurology 1998, 50:318. 1967.